Imunon (IMNN) risk factors
Item 1A of every Imunon, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors33 risks2 dropped6 reworded
Accumulated deficit rose to $421 million as net losses continued at $14.5 million in 2025. Financial disclosures updated figures for accumulated deficit and annual net losses.
Filed Mar 31, 2026 - FY2024 10-K risk factors35 risks
Imunon faces substantial going concern doubt with an accumulated deficit of $407 million as of December 31, 2024. Drug development relies entirely on third-party manufacturers, clinical investigators, and licensed technologies like Duke University's thermo-sensitive liposome technology. Commercial success depends heavily on regulatory milestones for IMNN-001, including FDA Fast Track and Orphan Drug designations.
Filed Feb 27, 2025